TWST - Twist Bioscience Corp Stock Price, Fair Value and News

29.23USD-1.45 (-4.73%)Market Closed

Market Summary

USD29.23-1.45

Market Closed

-4.73%

TWST Stock Price

View Fullscreen

TWST RSI Chart

TWST Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

-8.21

Price/Sales (Trailing)

6.44

EV/EBITDA

-8.26

Price/Free Cashflow

-13.12

TWST Price/Sales (Trailing)

TWST Profitability

Operating Margin

35.79%

EBT Margin

-77.99%

Return on Equity

-34.88%

Return on Assets

-28.08%

Free Cashflow Yield

-7.62%

TWST Fundamentals

TWST Revenue

Revenue (TTM)

262.4M

Rev. Growth (Yr)

31.81%

Rev. Growth (Qtr)

6.8%

TWST Earnings

Earnings (TTM)

-205.8M

Earnings Growth (Yr)

-2.83%

Earnings Growth (Qtr)

Breaking Down TWST Revenue

Last 7 days

-11.3%

Last 30 days

-13.1%

Last 90 days

-17.1%

Trailing 12 Months

109.2%

How does TWST drawdown profile look like?

TWST Financial Health

Current Ratio

5.98

Debt/Equity

Debt/Cashflow

-178.2

TWST Investor Care

Shares Dilution (1Y)

1.69%

Diluted EPS (TTM)

-3.61

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	227.8M	235.5M	245.1M	262.4M
2022	163.1M	184.2M	203.6M	215.8M
2021	113.0M	126.8M	132.3M	146.2M
2020	65.8M	73.4M	90.1M	101.1M
2019	40.0M	47.1M	54.4M	60.1M
2018	18.1M	21.8M	25.4M	32.6M
2017	0	0	10.8M	14.4M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Twist Bioscience Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 09, 2024	laponis adam	sold	-18,434	33.155	-556	chief financial officer
Apr 02, 2024	green paula	sold	-7,496	32.736	-229	svp of human resources
Apr 02, 2024	finn patrick john	sold	-16,106	32.736	-492	president and coo
Apr 02, 2024	banyai william	sold	-10,704	32.736	-327	see remark
Apr 02, 2024	leproust emily m.	sold	-37,057	32.736	-1,132	chief executive officer
Apr 02, 2024	cho dennis	sold	-4,222	32.736	-129	see remarks
Mar 20, 2024	banyai william	sold	-14,814	33.516	-442	see remark
Mar 20, 2024	cho dennis	sold	-7,708	33.516	-230	see remarks
Mar 20, 2024	leproust emily m.	sold	-37,806	33.516	-1,128	chief executive officer
Mar 20, 2024	green paula	sold	-6,703	33.516	-200	svp of human resources

Which funds bought or sold TWST recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 12, 2024	HARBOR INVESTMENT ADVISORY, LLC	new	-	995	995	-%
Apr 12, 2024	Global Trust Asset Management, LLC	unchanged	-	-77.00	1,029	-%
Apr 11, 2024	Opal Wealth Advisors, LLC	new	-	687	687	-%
Apr 11, 2024	ROCKLAND TRUST CO	unchanged	-	-98,175	1,320,940	0.07%
Apr 10, 2024	Banque Cantonale Vaudoise	unchanged	-	-2,000	28,000	-%
Apr 10, 2024	Green Alpha Advisors, LLC	reduced	-2.19	-50,889	517,566	0.38%
Apr 09, 2024	Rise Advisors, LLC	unchanged	-	-51.00	686	-%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	added	1.33	-18,238	302,923	-%
Apr 05, 2024	GAMMA Investing LLC	added	10.59	942	6,450	-%
Apr 05, 2024	CWM, LLC	added	0.31	-4,000	66,000	-%

Are Funds Buying or Selling TWST?

Are funds buying TWST calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TWST

No. of Funds

Unveiling Twist Bioscience Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.49%	5,475,322	SC 13G/A
Feb 12, 2024	william blair investment management, llc	6.2%	3,549,874	SC 13G
Feb 12, 2024	nikko asset management americas, inc.	6.21%	3,583,443	SC 13G/A
Feb 12, 2024	artisan partners limited partnership	6.4%	3,723,305	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 05, 2024	sumitomo mitsui trust holdings, inc.	6.21%	3,583,443	SC 13G/A
Jan 29, 2024	ark investment management llc	12.51%	7,213,257	SC 13G/A
Jan 25, 2024	state street corp	5.83%	3,362,215	SC 13G/A
Jan 25, 2024	jpmorgan chase & co	7.7%	4,462,494	SC 13G/A
Jan 25, 2024	jpmorgan chase & co	7.7%	4,462,494	SC 13G/A

Recent SEC filings of Twist Bioscience Corp

View All Filings

Date Filed	Form Type	Document
Apr 11, 2024	4	Insider Trading
Apr 09, 2024	144	Notice of Insider Sale Intent
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading
Apr 02, 2024	144	Notice of Insider Sale Intent
Apr 02, 2024	144	Notice of Insider Sale Intent
Apr 02, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Twist Bioscience Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	177.3B	23.9B	-3.91%	-4.78%	37.37	7.42	-10.33%	-33.23%
A	41.1B	6.7B	-4.92%	0.73%	33.25	6.1	-2.81%	-6.58%
IDXX	40.8B	3.7B	-7.22%	1.87%	48.33	11.16	8.72%	24.44%
DGX	14.2B	9.3B	0.30%	-9.60%	16.68	1.54	-6.38%	-9.73%
CRL	12.1B	4.1B	-8.95%	15.76%	25.51	2.93	3.86%	-2.39%
MEDP	11.9B	1.9B	-2.43%	101.48%	42.11	6.31	29.17%	15.26%
EXAS	11.9B	2.5B	13.24%	-2.16%	-58.11	4.75	19.93%	67.26%
NTRA	10.9B	1.1B	0.99%	75.89%	-25.11	10.08	31.99%	20.63%
MID-CAP
NEOG	2.6B	929.2M	-20.88%	-25.40%	1.7K	2.8	28.93%	111.61%
GH	2.1B	563.9M	-3.78%	-30.33%	-4.33	3.68	25.45%	26.76%
SMALL-CAP
CDNA	425.1M	280.3M	-19.03%	-7.55%	-2.23	1.52	-12.89%	-148.37%
ACRS	86.5M	31.2M	4.27%	-86.20%	-0.98	2.77	5.03%	-1.81%
AWH	41.5M	9.2M	-6.67%	-36.96%	-2.48	4.53	11.85%	44.12%
APDN	6.1M	9.0M	-2.70%	-65.71%	-0.85	0.68	-53.31%	2.21%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Twist Bioscience Corp News

Latest updates

Twist Bioscience Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	6.8%	71,498,000	66,946,000	63,740,000	60,180,000	54,243,000	57,306,500	56,113,000	48,127,000	42,018,000	37,950,500	35,018,000	31,204,000	28,161,000	32,432,000	21,207,000	19,297,000	17,164,000	15,736,500	13,600,000	13,557,000	11,492,000
Cost Of Revenue	0.3%	42,536,000	42,424,000	41,845,000	41,669,000	29,442,000	31,586,000	30,974,000	29,714,000	27,056,000	22,497,000	20,933,000	19,028,000	18,162,000	17,577,500	16,472,000	13,564,000	13,792,000	12,385,500	11,394,000	11,789,000	11,857,000
Costs and Expenses	1.2%	118,475,000	117,057,500	124,521,000	121,817,000	98,873,000	114,177,500	117,276,000	108,929,000	97,958,000	77,761,500	77,136,000	69,208,000	60,954,000	56,399,000	49,403,000	51,383,000	72,994,000	47,305,000	41,721,000	39,820,000	34,389,000
S&GA Expenses	11.5%	52,840,000	47,391,500	46,057,000	53,965,000	42,324,000	54,159,500	53,693,000	53,998,000	51,098,000	38,242,500	34,478,000	34,389,000	28,792,000	27,185,000	22,487,000	27,190,000	26,405,000	24,423,000	21,320,000	19,124,000	15,259,000
R&D Expenses	-2.7%	23,099,000	23,745,500	24,528,000	27,379,000	31,242,000	29,606,000	36,840,000	31,231,000	22,630,000	19,443,000	19,838,000	15,791,000	14,000,000	11,636,500	10,444,000	10,629,000	10,297,000	10,496,500	9,007,000	8,907,000	7,273,000
EBITDA Margin	7.5%	-0.66	-0.71	-0.77	-0.83	-0.91	-1.04	-1.11	-1.15	-1.14	-1.09	-1.01	-1.01	-	-	-	-	-	-	-	-	-
Interest Expenses	-100.0%	-	1,000	1,000	2,000	1,000	25,500	-	29,000	26,000	83,500	70,000	95,000	118,000	143,000	181,000	215,000	248,000	287,500	318,000	340,000	348,000
Income Taxes	154.1%	120,000	-222,000	622,000	676,000	76,000	292,000	-149,000	-149,000	-10,405,000	340,500	-2,377,000	61,000	46,000	262,500	21,000	61,000	37,000	112,000	54,000	84,000	43,000
Earnings Before Taxes	7.7%	-42,888,000	-46,465,000	-56,773,000	-58,480,000	-41,748,000	-50,823,000	-60,666,000	-60,817,000	-55,968,000	-40,901,500	-42,414,000	-37,858,000	-32,854,000	-24,055,500	-28,186,000	-31,707,000	-55,601,000	-31,069,000	-27,862,000	-25,849,000	-22,596,000
EBT Margin	6.1%	-0.78	-0.83	-0.88	-0.93	-0.99	-1.12	-1.19	-1.23	-1.21	-1.16	-1.08	-1.09	-	-	-	-	-	-	-	-	-
Net Income	7.0%	-43,008,000	-46,243,000	-57,395,000	-59,156,000	-41,824,000	-51,115,000	-60,517,000	-60,668,000	-45,563,000	-41,242,000	-40,037,000	-37,919,000	-32,900,000	-24,318,000	-28,207,000	-31,768,000	-55,638,000	-31,181,000	-27,916,000	-25,933,000	-22,639,000
Net Income Margin	6.0%	-0.78	-0.83	-0.89	-0.93	-0.99	-1.07	-1.13	-1.15	-1.13	-1.15	-1.07	-1.09	-	-	-	-	-	-	-	-	-
Free Cashflow	-6.0%	-24,479,000	-23,097,000	-27,921,000	-53,341,000	-65,894,000	-17,729,000	-74,767,000	-74,310,000	-59,436,000	-42,892,000	-34,902,000	-32,950,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-5.6%	733	776	810	854	910	961	980	1,022	786	702	725	677	700	399	408	324	192	187	207	140	164
Current Assets	-8.0%	390	424	446	489	542	596	624	664	385	546	577	608	634	335	345	260	129	160	183	121	147
Cash Equivalents	-7.1%	266	286	307	315	319	380	378	409	193	467	477	401	350	94.00	209	185	27.00	47.00	69.00	29.00	67.00
Inventory	-3.7%	31.00	32.00	36.00	40.00	45.00	39.00	43.00	45.00	40.00	32.00	21.00	16.00	13.00	12.00	13.00	11.00	7.00	7.00	5.00	4.00	6.00
Net PPE	-4.3%	126	132	141	147	145	139	127	92.00	65.00	44.00	38.00	32.00	27.00	25.00	24.00	23.00	21.00	21.00	20.00	15.00	14.00
Goodwill	0%	86.00	86.00	86.00	86.00	86.00	86.00	86.00	86.00	84.00	22.00	23.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-6.7%	143	153	153	150	164	172	159	158	140	121	115	63.00	62.00	63.00	59.00	60.00	89.00	35.00	31.00	25.00	26.00
Current Liabilities	-11.0%	65.00	73.00	73.00	72.00	84.00	91.00	93.00	85.00	80.00	63.00	55.00	40.00	37.00	36.00	31.00	30.00	58.00	30.00	25.00	19.00	19.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00	1.00	2.00	3.00	4.00	4.00	5.00	6.00	7.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00	1.00	2.00	3.00	4.00	4.00	5.00	6.00	7.00
Shareholder's Equity	-5.4%	590	623	658	704	746	789	821	863	626	581	610	614	638	336	349	264	103	152	176	115	139
Retained Earnings	-4.2%	-1,076	-1,033	-986	-929	-870	-828	-777	-716	-656	-610	-569	-529	-491	-458	-434	-405	-374	-318	-287	-259	-233
Additional Paid-In Capital	0.6%	1,667	1,657	1,645	1,633	1,617	1,620	1,599	1,581	1,282	1,191	1,179	1,143	1,129	795	783	670	477	470	463	375	372
Shares Outstanding	0.4%	58.00	58.00	57.00	57.00	56.00	57.00	56.00	52.00	50.00	48.00	48.00	49.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	833	-	-	-	2,390	-	-	-	4,885	-	-	-	1,088	-	-	-	402	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-11.0%	-22,973	-20,704	-23,412	-44,288	-54,070	-1,267	-34,125	-42,340	-46,653	-34,803	-27,960	-24,549	-24,932	-25,202	-23,468	-58,671	-34,914	-23,358	-22,082	-20,813	-21,684
Share Based Compensation	-6.2%	11,020	11,747	10,597	10,259	-2,325	19,048	20,043	22,465	18,108	9,247	9,176	11,553	7,022	5,131	4,071	4,197	3,697	3,363	3,032	2,911	1,864
Cashflow From Investing	285.4%	4,165	-2,247	18,670	41,160	-6,971	2,783	4,163	-13,294	-226,582	23,911	104,575	73,590	-45,921	-94,669	-61,149	28,763	12,405	-1,187	-22,706	-15,160	-65,757
Cashflow From Financing	-433.3%	-1,473	442	-661	1,525	-395	1,240	-1,311	271,616	-1,011	1,575	-765	1,451	326,921	5,574	108,064	188,037	2,057	2,928	84,285	-1,634	72,999
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

TWST Income Statement

2023-12-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)
shares in Thousands, $ in Thousands

3 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Statement of Comprehensive Income [Abstract]

Revenues

^[1]

$ 71,498

$ 54,243

Operating expenses:

Cost of revenues

42,536

29,442

Research and development

23,099

31,242

Selling, general and administrative

52,840

42,324

Change in fair value of contingent considerations and holdbacks

(4,135)

Total operating expenses

118,475

98,873

Loss from operations

(46,977)

(44,630)

Interest income

4,120

3,040

Interest expense

(1)

Other income (expense), net

(31)

(157)

Loss before income taxes

(42,888)

(41,748)

Income tax provision

(120)

(76)

Net loss attributable to common stockholders

(43,008)

(41,824)

Other comprehensive loss:

Change in unrealized (gain) loss on investments

134

(868)

Foreign currency translation adjustment

(366)

Comprehensive loss

$ (42,817)

$ (43,058)

Net loss per share attributable to common stockholders—basic (in usd per share)

$ (0.75)

$ (0.74)

Net loss per share attributable to common stockholders—diluted (in usd per share)

$ (0.75)

$ (0.74)

Weighted average shares used in computing net loss per share attributable to common stockholders—basic (in shares)

57,497

56,444

Weighted average shares used in computing net loss per share attributable to common stockholders—diluted (in shares)

57,497

56,444

[1]	During the three months ended December 31, 2023, and 2022, the Company had revenues from the related parties in the amount of $2.3 million and $0.2 million, respectively.

TWST Balance Sheet

2023-12-31

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Dec. 31, 2023	Sep. 30, 2023
Current assets:
Cash and cash equivalents	$ 266,269	$ 286,470
Short-term investments	44,875	49,943
Accounts receivable, net	35,354	44,064
Inventories	30,863	32,063
Prepaid expenses and other current assets	12,870	11,716
Total current assets	390,231	424,256
Property and equipment, net	126,225	131,830
Operating lease right-of-use assets	69,093	71,531
Goodwill	85,811	85,811
Intangible assets, net	53,190	54,483
Restricted cash, non-current	2,847	2,811
Other non-current assets	5,418	5,681
Total assets	732,815	776,403
Current liabilities:
Accounts payable	9,256	14,052
Accrued expenses	13,959	10,754
Accrued compensation	20,787	25,818
Current portion of operating lease liability	14,808	14,896
Other current liabilities	6,418	7,803
Total current liabilities	65,228	73,323
Operating lease liability, net of current portion	77,070	79,173
Other non-current liabilities	475	475
Total liabilities	142,773	152,971
Commitments and contingencies (Note 6)
Stockholders’ equity
Common stock, $0.00001 par value —100,000 and 100,000 shares authorized at December 31, 2023 and September 30, 2023, respectively; 57,779 and 57,557 shares issued and outstanding at December 31, 2023 and September 30, 2023, respectively	0	0
Additional paid-in capital	1,666,797	1,657,222
Accumulated other comprehensive income	(565)	(756)
Accumulated deficit	(1,076,190)	(1,033,034)
Total stockholders’ equity	590,042	623,432
Total liabilities and stockholders’ equity	$ 732,815	$ 776,403

About Twist Bioscience Corp

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

CEO	Dr. Emily Marine Leproust Ph.D.
WEBSITE	twistbioscience.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	989

Twist Bioscience Corp Frequently Asked Questions

What is the ticker symbol for Twist Bioscience Corp? What does TWST stand for in stocks?

TWST is the stock ticker symbol of Twist Bioscience Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Twist Bioscience Corp (TWST)?

As of Mon Apr 15 2024, market cap of Twist Bioscience Corp is 1.69 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TWST stock?

You can check TWST's fair value in chart for subscribers.

What is the fair value of TWST stock?

You can check TWST's fair value in chart for subscribers. The fair value of Twist Bioscience Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Twist Bioscience Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TWST so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Twist Bioscience Corp a good stock to buy?

The fair value guage provides a quick view whether TWST is over valued or under valued. Whether Twist Bioscience Corp is cheap or expensive depends on the assumptions which impact Twist Bioscience Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TWST.

What is Twist Bioscience Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, TWST's PE ratio (Price to Earnings) is -8.21 and Price to Sales (PS) ratio is 6.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TWST PE ratio will change depending on the future growth rate expectations of investors.